Clinical trials: Phosphate Diabetes
Diabetic Cardiomyopathy
Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes
Diabetes increases the risk of heart failure. This is mainly due to a disease of the blood vessels supplying the heart muscle and/or high blood pressure, but abnormal metabolism may also contribute.
- Trial name
- DDCM (NCT00628056)
- Testing
- Perhexiline
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University Hospital Birmingham
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124560
- Testing
- Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Type 2 Diabetes, Novel Brominated Flame Retardants
Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes
As alternative flame retardants (FRs), novel brominated flame retardants (NBFRs) and organophosphate flame retardants (OPFRs) are ubiquitous in environment and may cause endocrine disruption effects.
- Conditions
- Type 2 Diabetes, Novel Brominated Flame Retardants, Organophosphate Flame Retardants, Fasting Plasma Glucose
- Trial name
- NCT06239506
- Testing
- no intervention
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Xiaoling Guan
Diabetic Peripheral Neuropathy
Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)
This study will be an observational study in which patients who have been prescribed Metanx® are invited to participate in surveys regarding their experiences with Metanx®.
- Trial name
- NCT01368549
- Testing
- Metanx® (a medical food)
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Pamlab, L.L.C.
Diabetes Mellitus, Type 2
A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)
The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.
- Trial name
- NCT01357148
- Testing
- Sitagliptin Phosphate/Metformin HCl (JANUMET®)
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
Retagliptin phosphate tablet is a DPP IV inhibitor durg，study number is HR-SP2086-304. The primary purpose of the study is to evaluate the efficacy of the combination of Retagliptin phosphate and metformin compared with placebo…
- Trial name
- NCT05054842
- Testing
- Retagliptin phosphate tablets、metformin sustained-release tablets
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Kidney Disease stage3
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of orally drugs for the treatment of type 2 diabetes. These drugs decrease plasma glucose levels by inhibiting its reabsorption in the proximal tubules of the…
- Trial name
- NCT04961931
- Testing
- Empagliflozin 10 MG
- Where
- Poland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz